The aim of this study was to evaluate the haemodynamic effects of serelaxin (30 µg/kg/day 20-h infusion and 4-h post-infusion period) in patients with acute heart failure (AHF).

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure / Ponikowski, Piotr; Mitrovic, Veselin; Ruda, Mikhail; Fernandez, Alberto; Voors, Adriaan A; Vishnevsky, Alexander; Cotter, Gad; Milo, Olga; Laessing, Ute; Zhang, Yiming; Dahlke, Marion; Zymlinski, Robert; Metra, Marco. - In: EUROPEAN HEART JOURNAL. - ISSN 1522-9645. - 35:7(2014), pp. 431-441. [10.1093/eurheartj/eht459]

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure

METRA, Marco
2014-01-01

Abstract

The aim of this study was to evaluate the haemodynamic effects of serelaxin (30 µg/kg/day 20-h infusion and 4-h post-infusion period) in patients with acute heart failure (AHF).
2014
Acute heart failure
Clinical trial
Haemodynamics
Serelaxin
Aged
Analysis of Variance
Blood Pressure
Cardiotonic Agents
Double-Blind Method
Female
Glomerular Filtration Rate
Heart Failure
Hemodynamics
Humans
Infusions
Intravenous
Male
Pulmonary Wedge Pressure
Recombinant Proteins
Relaxin
Vascular Resistance
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/193925
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 105
  • ???jsp.display-item.citation.isi??? 100
social impact